Global Renal Dialysis Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Renal Dialysis Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Renal dialysis is a procedure wherein toxic substances, such as urea and creatinine, are removed from the body. This procedure is one of the lifesaving treatments for a patient who has suffered from kidney failure due to chronic renal disease.

Market Overview:

The latest research study on the global Renal Dialysis market finds that the global Renal Dialysis market reached a value of USD 107039.0 million in 2022. It’s expected that the market will achieve USD 143562.0 million by 2028, exhibiting a CAGR of 5.01% during the forecast period.

Impact on Cost of Raw Materials and Product

Affected by economic laws and other objective factors, during the COVID-19 epidemic, renal dialysis equipment and medicines will appear to be in short supply due to continuous demand or skyrocketing demand. Therefore, when demand exceeds supply, prices will rise. At the same time, part of the logistics is out of service and the capacity is insufficient, which will lead to an increase in transportation costs and one of the reasons for rising prices. The medical equipment industry played a vital role in this epidemic. Disposable raw materials and packaging cartons have increased several times.
In addition, due to the sudden increase in demand for chip resistor products in renal dialysis equipment, many companies do not hesitate to increase prices and reserve. As a result, the prices of components such as sensors, resistors, and capacitors have risen significantly. It is expected that when the COVID-19 epidemic is over, all regions will resume work, commodities can circulate freely, production capacity can be restored, and renal dialysis equipment and pharmaceutical raw materials will be reduced to normal prices due to increased production.

Impact on Availability of Products

Manufacturers of renal dialysis equipment and drugs cannot simply fail to conduct usability testing due to COVID-19. Both IEC 62366-1 and the FDA insist on conducting these tests, and there are no exceptions due to the coronavirus. Even during the epidemic, manufacturers of renal dialysis equipment and medicines can pass appropriate safety strategies to ensure that they not only comply with safety requirements, but also carry out usability tests to meet the prerequisites for equipment approval.
Therefore, at least in the short term, the impact on these renal dialysis equipment and pharmaceutical companies will be considerable. Inventory is overstocked, and rental and labor costs will continue to be invested. For at least half a year, these renal dialysis equipment and pharmaceutical manufacturers will face great survival pressure, especially a group of small and medium-sized enterprises.

Fierce Market Competition

The Renal Dialysis industry has been more and more competitive, and it is technology oriented, which comes with high cost. If the company cannot correctly grasp the market dynamics and industry development trends, it cannot further consolidate its dominant position and ensure its core in product research and development, market expansion, etc. There are market competition risks such as decline in business performance and decline in market share due to weakened competitive advantages. Moreover, there are an increasing number of competitors entering the market, which means the technology and professional knowledge of this industry are no longer unavailable. If the players still provide roughly the same products or services, or at least few obvious differences; Or if the players continue to compete on price in Renal Dialysis solutions, avoiding enhancing products or services with features and technological content that could increase costs, it will be hard for them to sustain the fierce market. Therefore, companies in the Renal Dialysis market must increase their R&D activities in order to gain a competitive edge over other market players.

Regulatory Backing to Novel Products to Encourage Innovation among Players

Development of innovative dialysis solutions has been the mainstay strategy of majority of the players in this market. These innovations are finding strong support from regulatory bodies such as the US Food and Drug Administration (FDA), which is further encouraging other players to invest in R&D and bring out unique solutions for kidney patients. US FDA approval for novel renal care devices of Fresenius is propelling its market share. For instance, in October 2019, the USFDA granted breakthrough device designation to its new hemodialysis system currently in development, designed to prevent blood clotting without the use of blood thinners in patients.

Shift of Patients from Clinics to Homecase Settings

Patients with end-stage renal disease (ESRD) are required to undergo treatment at renal facilities or they can opt for these services at home. Rising preference of patients for receiving care at home, especially in the developed economies, is one of the key trends in the market. Also, governments in nations such as the U.S. are engaged in setting up new payment methods for treating kidney disease, which can favor lower cost care at home. This is estimated to propel the number of patients opting for treatment in home care settings in coming years.
Therefore, the growing preference for home hemodialysis treatment serves as an opportunity for companies, providing a direction for corporate technology innovation to produce cost-effective and accurate portable dialysis apparatu, which is expected to boost market growth.

Region Overview:

Geographically, USA held the largest market share – 26.08% in 2022.

Company Overview:

Fresenius Medical Care AG & Co. KGaA is one of the major players operating in the Renal Dialysis market, holding a share of 19.5% in 2023.

Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure.

DaVita Healthcare Partners, Inc.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services.

Segmentation Overview:

As for product types, the Primary Dialysis segment held the largest market share in 2022.

Application Overview:

The market's largest segment by application is the segment Dialysis Centers, with a market share of 64.47% in 2022.

Key Companies in the global Renal Dialysis market covered in Chapter 3:

DaVita Healthcare Partners, Inc.
Cantel
Fresenius Medical Care AG & Co. KGaA
Medtronic
Baxter
Nikkiso
Nipro
B. Braun
Asahi Kasei Corporation

In Chapter 4 and Chapter 14.2, on the basis of types, the Renal Dialysis market from 2018 to 2029 is primarily split into:

Primary Dialysis
Secondary Dialysis

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Renal Dialysis market from 2018 to 2029 covers:

Hospitals
Dialysis Centers
Home Care Settings

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)